Antimicrobial Susceptibility Testing Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global antimicrobial susceptibility testing market growth forecasted to transform from USD 3.6 billion in 2022 to USD 4.7 billion by 2027, driven by a CAGR of 5.5%. The high prevalence of infectious diseases, rising government funding and initiatives for antimicrobial susceptibility testing programs, technological developments for the creation of new AST methods, and the emergence of multidrug resistance in microorganisms are the main factors driving the market growth. However, strict government controls are anticipated to limit this market's expansion to some degree. Players in the antimicrobial susceptibility testing market may anticipate having tremendous growth potential as a result of emerging markets and ongoing R&D to provide quick antimicrobial susceptibility testing.

Antimicrobial Susceptibility Testing Market Trends

e- Estimated; p- Projected

To know about the assumptions considered for the study, Request for Free Sample Report

Antimicrobial Susceptibility Testing Market Dynamics

Driver: Emergence of multidrug resistance due to drug abuse

As medication resistance increases internationally, making diseases harder to cure and ultimately to mortality, antibiotics are becoming less and less effective. According to the WHO priority pathogen list, new antibiotics are urgently needed, for instance, to treat carbapenem-resistant gram-negative bacterial infections. Unfortunately, these novel medicines will experience the same destiny as the present antibiotics and become useless if people do not modify the way antibiotics are used currently.

Opportunity: Growth opportunities in emerging market

Emerging countries such as APAC, India, China and Japan present significant opportunities for players operating in the Antimicrobial susceptibility testing market. The demand for Antimicrobial susceptibility testing market in these countries is increasing owing to rapid growth in medical tourism, the growing adult (aged 20 and above) population, increasing drug abuse. These countries are also home to a strong and qualified workforce and have a great knowledge of advance technologies. Furthermore, these countries have lenient policies for imports/exports and are underpenetrated in most aspects, which could help companies in brand development. Increasing developing technicians and the keen to know about new technologies is helping the regions to grow and update their technologies.

Challenge: Complex Regulatory Frameworks

The time gap between defining clinical breakpoints, approving novel antimicrobial drugs, and putting these medicines on the market is one of the biggest problems with antimicrobial susceptibility testing. When pharmaceutical companies submit unapproved new medication applications, the FDA determines certain cutoff criteria. Adoption of antimicrobial susceptibility products is further constrained by the lack of clinical breakpoints for certain medications. For example, there are no clinical cutoffs available to determine antifungal treatment efficacy in invasive non-Aspergillus mold infections.

Restraint: High Cost of automated Laboratory Instruments

Automated antimicrobial laboratory equipment has top-of-the-line features and functions, and it costs a lot of money. The incubation and detection times are shortened by the use of automated AST systems. The high cost of maintenance for these devices, which are well-equipped with cutting-edge software that requires routine upkeep, is another hurdle to this industry.

By product type, the automated laboratory instruments segment accounted for the largest share of the antimicrobial susceptibility testing industry during the forecast period.

In 2022, automated laboratory instruments accounted for the largest share of in the antimicrobial susceptibility testing market. This segment is projected to reach USD 1.5 billion by 2027 from USD 1.7 billion in 2022, at a CAGR of 6.9% during the forecast period.

By End User, Hospitals and diagnostic center segment of antimicrobial susceptibility testing industry is expected to grow at the fastest rate during the forecast period.

In 2022, hospitals and diagnostic centers holds a larger share In the antimicrobial susceptibility testing market with a share of 63.5%. This end-user segment is projected to reach USD 2.9 billion by 2027 from USD 2.2 billion in 2022, at a CAGR of 5.7% during the forecast period. This end-user segment is also expected to grow at the highest CAGR of 5.7% during the forecast period.

North America is expected to be the largest market of the antimicrobial susceptibility testing industry during the forecast period.

The highest portion of the global antimicrobial susceptibility testing market—35.4%—is accounted for by North America. US and Canada make up North America. The high frequency of illnesses for which pre-tests are required, the growing elderly population, and the appearance of novel bacterial, fungal, and viral strains in North America are the reasons why North America has the biggest proportion. Due to rising drug addiction, misuse, and non-compliance, the APAC area is developing at the highest CAGR of 6.7%.

To know about the assumptions considered for the study, download the pdf brochure

The antimicrobial susceptibility testing market is moderately competitive, with both established companies and upcoming competitors for the same market share. The key players operating in this market include bioMérieux SA (France), Becton, Dickinson, and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US) among others.

Antimicrobial Susceptibility Testing Market Report Scope

This report has segmented the Antimicrobial susceptibility testing market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Manual Antimicrobial Susceptibility Testing Product
  • Susceptibility Testing Disks
  • Mic Strips
  • Susceptibility Plates
• Automated Laboratory Instruments
• Culture and Growth Media
• Consumables

By Type

• Antibacterial susceptibility testing
• Antifungal susceptibility testing
• Antiparasitic susceptibility testing
• Other susceptibility testing

By Method

• Etest Method
• Disk Diffusion
• Automated Susceptibility testing instruments
• Agar Diffusion
• Genotyping method

By Application

• Clinical Diagnostics
• Drug Discovery and development
• Epidemiology
• Other applications

By End User

• Hospitals and Diagnostic centers
• Pharmaceutical and Biotechnology Companies
• Research &Academic Institutes
• Clinical Research Organizations

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa

Recent Developments of Antimicrobial Susceptibility Testing Market

• In Jan,2023 bioMerieux launched a automated instrument named MAESTRIA
• In Aug,2022 BD India launched the BD MAX MDR-TB panel.
• In May ,2022 Thermofisher scientific introduced automated antimicrobial susceptibility products.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst